CMPX — Compass Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1738021 ·
Last close
$0.98
Market Cap
$177.10M
52W High
$6.88
52W Low
$0.83
ADV30
5,660,631
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -26,979,000 | -25,154,000 | 190,173,000 | 35,453,000 | 24,124,000 |
| Mar 2026 | 0 | — | -20,299,000 | -18,317,000 | 205,170,000 | 55,168,000 | 18,697,000 |
| Dec 2025 | 0 | — | -17,990,000 | -15,716,000 | 219,588,000 | 30,643,000 | 22,797,000 |
| Sep 2025 | 0 | — | -15,817,000 | -14,259,000 | 231,259,000 | 46,212,000 | 21,646,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,110,000
Investing CF
$-65,082,000
Financing CF
$133,789,000
CapEx
$-283,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-474,643,000
Inventory
—
Receivables
—
ST Investments
$144,426,000
EBIT TTM
$-81,085,000
Pretax Income TTM
$-73,446,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -72,839,000 | -66,489,000 | 219,588,000 | 22,797,000 | 196,791,000 | -49,143,000 |
| Dec 2024 | 850,000 | -56,625,000 | -49,375,000 | 140,403,000 | 15,170,000 | 125,233,000 | -44,855,000 |
| Dec 2023 | 0 | -50,363,000 | -42,494,000 | 156,875,000 | 8,337,000 | 148,538,000 | -40,618,000 |
| Dec 2022 | 0 | -41,655,000 | -39,225,000 | 199,645,000 | 18,007,000 | 181,638,000 | -34,125,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-68,173,000
OpCashFlow TTM
—
Assets (Latest)
$205,170,000
Forward EPS
$-0.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DTIL | PRECISION BIOSCIENCES INC | $177.48M | $6.43 | — |
| IPHYF | Innate Pharma SA | $168.56M | $1.51 | — |
| IPHA | Innate Pharma SA | $165.32M | $1.48 | — |
| CHRS | Coherus Oncology, Inc. | $165.32M | $1.07 | — |
| ACOG | Alpha Cognition Inc. | $196.87M | $9.04 | — |
News headlines (Yahoo Finance, 1h cache)
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’
2026-09-23 13:44 · Yahoo
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
2026-09-22 23:07 · Yahoo
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
2026-09-22 18:02 · Yahoo
CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing
2026-09-22 14:43 · Yahoo
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
2026-07-17 14:42 · Yahoo
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
2026-06-08 13:06 · Yahoo
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
2026-05-21 21:00 · Yahoo
Compass Therapeutics to Participate in Upcoming May Investor Events
2026-05-12 11:30 · Yahoo
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
2026-05-05 11:30 · Yahoo
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)
2026-05-05 12:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.